Home > Boards > US Listed > Biotechs > NantKwest (NK)

I have to admit that I'm surprised to

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
knoxlube Member Profile
 
Followed By 6
Posts 1,444
Boards Moderated 0
Alias Born 05/08/11
160x600 placeholder
Annual Report (10-k) Edgar (US Regulatory) - 3/25/2020 4:11:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/24/2020 5:48:16 PM
NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy With Off-the-Shelf CD16... Business Wire - 3/19/2020 8:00:00 AM
Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference Business Wire - 1/16/2020 8:00:00 AM
NantKwest & ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy Wit... Business Wire - 12/16/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/12/2019 6:30:19 PM
NantKwest Announces Phase 1 Results for First-in-Human PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) in Patients w... Business Wire - 12/2/2019 4:05:00 PM
NantKwest Hosting Key Opinion Leader Meeting on Novel Immunotherapeutic Approaches to Address the Unmet Medical Needs of Pati... Business Wire - 11/27/2019 8:00:00 AM
NantKwest Announces Presentation of Positive Phase 2 Clinical Data of Natural Killer Cell Therapy in Metastatic Merkel Cell C... Business Wire - 11/7/2019 4:15:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2019 4:08:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/9/2019 4:43:47 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/4/2019 6:01:00 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 8/23/2019 4:10:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/7/2019 4:05:50 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/7/2019 4:02:57 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2019 4:09:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/5/2019 5:47:09 PM
NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patient... Business Wire - 6/24/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/10/2019 4:04:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:48:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:45:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:42:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:40:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:36:37 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 6/7/2019 4:32:37 PM
knoxlube   Monday, 03/25/19 02:20:10 PM
Re: None
Post # of 1258 
I have to admit that I'm surprised to see such a spike in volume and PPS just because SOON exercised his Warrants at $2. Maybe that signaled that NK shares are worth at least that much now and probably more later. I'm not really sure what to make of it all except I sold all my shares between $1.7-1.80, but may regret that later. Will see. Just wish some of this good happening with NK carried over to my MUCH bigger investment and Soon's partner in one of his key licensed drugs, Aldox, and it's developer, CYTR!

All IMO. GLTA in NK and CYTR!

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist